Zubir Ahmed moved unusually quickly from Parliament's back benches into government. Labour selected him to contest Glasgow South West, a seat the party had missed by only 60 votes in 2017. In July 2024 he defeated the SNP's Chris Stephens by 3,285 votes, becoming part of the Scottish Labour revival that helped deliver Keir Starmer's majority.

His standing rested heavily on his NHS experience. Labour first placed him inside the health team as a parliamentary aide to Wes Streeting, then promoted him to junior health minister in September 2025. The rapid rise suggested that Streeting regarded him as a useful clinical voice and a reliable ally. It also meant Ahmed acquired responsibility before he had established an independent parliamentary record.

His ministerial brief covered health innovation, patient safety, medicines regulation and clinical research. The clearest result delivered during his eight months in office was a substantial reduction in the time needed to establish commercial clinical trials. The average fell from 169 days to 122 days, beating the government's 150-day target. Regulatory reviews were generally being completed within 60 days, while 99 per cent met their required deadlines.

Ahmed did not produce this alone. The programme began before his appointment and involved the Department of Health, the NHS, regulators and research bodies. But he did have responsibility for driving it through its final stages, demanding regular performance reports and tying some research funding to delivery targets. The government backed the changes with £137 million for research infrastructure and reform. New regulations also created a faster route for lower-risk trial changes and made trial registration and publication of summary results compulsory for the first time. This was measurable delivery, not another vague promise to "unlock innovation".

Ahmed also helped introduce changes intended to give NHS patients faster access to new medicines. A UK-US pharmaceutical agreement raised the amount NICE could regard as cost-effective and led to two cancer treatments being recommended under the new threshold. The deal protected pharmaceutical exports from US tariffs, but it also committed Britain to doubling expenditure on innovative medicines as a share of GDP over ten years and capped the rebate manufacturers pay on branded NHS drugs.

Ahmed presented this as an uncomplicated gain for patients. It was not. Wider access to medicines carries a substantial cost, estimated by the government at around £1 billion during the spending-review period, and that money must come from the health budget. Two approved treatments showed an immediate benefit, but the government had not demonstrated that the wider settlement would produce better value than spending the same money on staffing, diagnostics or existing services. Ahmed helped sell the agreement but did little publicly to confront that trade-off.

His approach to NHS data exposed a similar tension. As minister, he defended the principles behind the NHS Federated Data Platform and said it was exceeding its targets, despite concern about the £330 million contract with Palantir, the company's political associations and the risk of dependence on one supplier. He left open the possibility of changing provider at a contractual break point, but did not secure publication of the evidence needed to test the government's performance claims.

After leaving office, Ahmed warned that the Health Bill amounted to one of the largest NHS reorganisations in modern times and demanded clearer answers about who would control patients' information. The concern was legitimate, but late. The data-driven model had been central to the programme he promoted in government. His record therefore shows greater confidence in technology and industry partnerships than in public scrutiny of how those systems are procured and governed.

Ahmed's ministerial career ended through a political choice rather than dismissal. Following Labour's disastrous 2026 election results, particularly Scottish Labour's fall to a record-low 17 MSPs, he resigned on 12 May and declared Starmer's position "wholly untenable". He said voters had repeatedly identified the Prime Minister as their reason for abandoning Labour. As a Streeting ally, his departure formed part of a wider ministerial revolt, but it was still a serious sacrifice for an MP promoted only eight months earlier. He gave up office when remaining would have been easier.

That resignation revealed more political nerve than his earlier record had suggested. Ahmed had initially risen through loyalty and specialist usefulness. When the leadership became electorally indefensible, he broke with it openly.

His completed record is short but not empty. He helped turn a clinical-trials target into a measured reduction from 169 to 122 days and oversaw regulatory changes with practical consequences for researchers and patients. Against that, his claims for pharmaceutical spending and NHS data systems ran ahead of the published evidence, while much of his wider health programme remained unfinished when he resigned. He proved capable of administering a technical brief and, eventually, of putting his office at risk. He was less convincing when asked to challenge the costs, commercial interests and loss of public control hidden beneath the language of NHS innovation.